Structured Review

Boehringer Ingelheim e selectin
Transmission electron and confocal laser microscopy of MPs. Transmission electron microscopy appearance of MPs generated in vitro ( a ) or in vivo ( e ), i.e., isolated from normal plasma (final magnification: ×25,000). In confocal laser microscopy, MPs appeared as elements with a diameter less than 1 μm and stained for αvβ3 ( c ) and <t>E-selectin</t> ( d ) in vitro. In vivo–generated MPs expressed αvβ3 ( g ) and CD41/GPIIb-IIIa ( h ). In this case, the majority of the elements were positive for CD41 ( h ), whereas only about 10% were positive for αvβ3 ( g ), confirming that they originate from ECs (final magnification: ×1,000). ( b and f ) Negative staining using isotope control IgG1.
E Selectin, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 92/100, based on 25 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/e selectin/product/Boehringer Ingelheim
Average 92 stars, based on 25 article reviews
Price from $9.99 to $1999.99
e selectin - by Bioz Stars, 2020-07
92/100 stars

Images

1) Product Images from "In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant"

Article Title: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant

Journal: Journal of Clinical Investigation

doi:

Transmission electron and confocal laser microscopy of MPs. Transmission electron microscopy appearance of MPs generated in vitro ( a ) or in vivo ( e ), i.e., isolated from normal plasma (final magnification: ×25,000). In confocal laser microscopy, MPs appeared as elements with a diameter less than 1 μm and stained for αvβ3 ( c ) and E-selectin ( d ) in vitro. In vivo–generated MPs expressed αvβ3 ( g ) and CD41/GPIIb-IIIa ( h ). In this case, the majority of the elements were positive for CD41 ( h ), whereas only about 10% were positive for αvβ3 ( g ), confirming that they originate from ECs (final magnification: ×1,000). ( b and f ) Negative staining using isotope control IgG1.
Figure Legend Snippet: Transmission electron and confocal laser microscopy of MPs. Transmission electron microscopy appearance of MPs generated in vitro ( a ) or in vivo ( e ), i.e., isolated from normal plasma (final magnification: ×25,000). In confocal laser microscopy, MPs appeared as elements with a diameter less than 1 μm and stained for αvβ3 ( c ) and E-selectin ( d ) in vitro. In vivo–generated MPs expressed αvβ3 ( g ) and CD41/GPIIb-IIIa ( h ). In this case, the majority of the elements were positive for CD41 ( h ), whereas only about 10% were positive for αvβ3 ( g ), confirming that they originate from ECs (final magnification: ×1,000). ( b and f ) Negative staining using isotope control IgG1.

Techniques Used: Transmission Assay, Microscopy, Electron Microscopy, Generated, In Vitro, In Vivo, Isolation, Staining, Negative Staining

2) Product Images from "BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections"

Article Title: BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections

Journal: Clinical and Experimental Immunology

doi: 10.1046/j.1365-2249.2003.02197.x

Linear BPI epitopes recognized by BPI–ANCA IgG of TAP-deficient patients. Binding of patients’ IgG to cellulose-bound peptides was performed as described in Methods. Numbering of amino acid sequence is according to the sequence of rBPI published by Beamer et al ]. Shown are residues 1–456. Regions recognized by IgG from BPI–ANCA positive patients’ and goat anti-BPI antiserum are shown as horizontal bars. Regions that retain endotoxin neutralizing and antibiotic activity are shown in bold italics.
Figure Legend Snippet: Linear BPI epitopes recognized by BPI–ANCA IgG of TAP-deficient patients. Binding of patients’ IgG to cellulose-bound peptides was performed as described in Methods. Numbering of amino acid sequence is according to the sequence of rBPI published by Beamer et al ]. Shown are residues 1–456. Regions recognized by IgG from BPI–ANCA positive patients’ and goat anti-BPI antiserum are shown as horizontal bars. Regions that retain endotoxin neutralizing and antibiotic activity are shown in bold italics.

Techniques Used: Binding Assay, Sequencing, Activity Assay

Antibacterial activity of rBPI and rBPI 21 against E. coli DH5α is inhibited by patients’ BPI–ANCA in vitro . Effects of purified IgG preparations from BPI–ANCA-positive patients in a constant concentration of 250 µg/ml on the antibiotic activity of rBPI (a) and rBPI 21 (b) against E. coli DH5α were measured as described in Methods. Pooled human IgG served as negative control, purified IgG from goat anti-BPI antiserum served as positive control. The results shown represent the mean of at least three experiments. For clarity, error bars have been left out; variation was
Figure Legend Snippet: Antibacterial activity of rBPI and rBPI 21 against E. coli DH5α is inhibited by patients’ BPI–ANCA in vitro . Effects of purified IgG preparations from BPI–ANCA-positive patients in a constant concentration of 250 µg/ml on the antibiotic activity of rBPI (a) and rBPI 21 (b) against E. coli DH5α were measured as described in Methods. Pooled human IgG served as negative control, purified IgG from goat anti-BPI antiserum served as positive control. The results shown represent the mean of at least three experiments. For clarity, error bars have been left out; variation was

Techniques Used: Activity Assay, In Vitro, Purification, Concentration Assay, Negative Control, Positive Control

Inhibition of antibacterial activity of rBPI 21 against E.coli DH5α by BPI–ANCA IgG can be reversed by preabsorption on rBPI 21 . Preabsorption of BPI–ANCA IgG from patient 2 was performed using either an rBPI 21 coated (8 µg/ml), an E.coli DH5α coated (heat-inactivated, 10 6 /ml) or an uncoated ELISA plate prior to use in the growth inhibition assay. Results show the mean of two experiments.
Figure Legend Snippet: Inhibition of antibacterial activity of rBPI 21 against E.coli DH5α by BPI–ANCA IgG can be reversed by preabsorption on rBPI 21 . Preabsorption of BPI–ANCA IgG from patient 2 was performed using either an rBPI 21 coated (8 µg/ml), an E.coli DH5α coated (heat-inactivated, 10 6 /ml) or an uncoated ELISA plate prior to use in the growth inhibition assay. Results show the mean of two experiments.

Techniques Used: Inhibition, Activity Assay, Enzyme-linked Immunosorbent Assay, Growth Inhibition Assay

Related Articles

Mutagenesis:

Article Title: Weak IgG self‐ and hetero‐association characterized by fluorescence analytical ultracentrifugation
Article Snippet: .. The 6 mAb IgGs differing in variable regions each constructed in IgG1 and IgG4Pro (IgG4 with S→P mutation in the hinge region) isotypes were provided by Boehringer Ingelheim. .. Human male AB plasma serum was purchased from Sigma‐Aldrich (cat# H4522) and purified with the ÄKTA affinity chromatography system and MabSelect Sure resin (GE Healthcare) following standard methods.

Construct:

Article Title: Weak IgG self‐ and hetero‐association characterized by fluorescence analytical ultracentrifugation
Article Snippet: .. The 6 mAb IgGs differing in variable regions each constructed in IgG1 and IgG4Pro (IgG4 with S→P mutation in the hinge region) isotypes were provided by Boehringer Ingelheim. .. Human male AB plasma serum was purchased from Sigma‐Aldrich (cat# H4522) and purified with the ÄKTA affinity chromatography system and MabSelect Sure resin (GE Healthcare) following standard methods.

Concentration Assay:

Article Title: IFN-gamma regulation of ICAM-1 receptors in bronchial epithelial cells: soluble ICAM-1 release inhibits human rhinovirus infection
Article Snippet: .. NHBE cells were incubated with ICAM-1 monoclonal antibody at a concentration of 5 μg/ml, (R1/1.1, IgG Boehringer Ingelheim, USA) at room temperature for 30 mins. .. After washing thoroughly with PBS, a secondary anti-mouse IgG FITC conjugated antibody (Sigma Aldrich, Dorset, UK) used at 1:500 dilution for 30 minutes at room temperature.

Incubation:

Article Title: IFN-gamma regulation of ICAM-1 receptors in bronchial epithelial cells: soluble ICAM-1 release inhibits human rhinovirus infection
Article Snippet: .. NHBE cells were incubated with ICAM-1 monoclonal antibody at a concentration of 5 μg/ml, (R1/1.1, IgG Boehringer Ingelheim, USA) at room temperature for 30 mins. .. After washing thoroughly with PBS, a secondary anti-mouse IgG FITC conjugated antibody (Sigma Aldrich, Dorset, UK) used at 1:500 dilution for 30 minutes at room temperature.

other:

Article Title: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant
Article Snippet: FITC-conjugated mAb to vitronectin receptor (anti-αvβ3 or anti-CD51, clone AMF7, IgG1) was from Immunotech (Marseille, France), and FITC-conjugated mAb to E-selectin (anti-CD62E, clone CI26CIOB7, IgG2a) was from Boehringer Ingelheim Bioproducts (Gagny, France).

Article Title: Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Article Snippet: We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelheim, Ingelheim, Germany), a humanised monoclonal antibody targeting the p19 subunit of interleukin-23, in patients with moderately-to-severely active Crohn's disease.

Binding Assay:

Article Title: Development and evaluation of an indirect enzyme-linked immunosorbent assay for serological detection of Schmallenberg virus antibodies in ruminants using whole virus antigen
Article Snippet: .. A HRP conjugated monoclonal antibody anti-bovine IgG1 also binding to ovine and caprine IgG (Boehringer Ingelheim Svanova, Sweden) was used as conjugate. .. Western blot analysis The antigen consisting of the A + B combination were separated on 10% SDS-PAGE and transferred onto a 0.45 μm nitrocellulose membrane (Bio-Rad) at 100 V for 1 h with a Criterion™ Blotter (Bio-Rad).

Article Title: Antibodies to watch in 2020
Article Snippet: .. Risankizumab (Boehringer Ingelheim, AbbVie) Risankizumab (risankizumab-rzaa, SKYRIZI™) is a humanized IgG1 monoclonal antibody that inhibits interleukin (IL)-23, a cytokine involved in inflammatory processes, by binding to its p19 subunit. ..

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Boehringer Ingelheim e selectin
    Transmission electron and confocal laser microscopy of MPs. Transmission electron microscopy appearance of MPs generated in vitro ( a ) or in vivo ( e ), i.e., isolated from normal plasma (final magnification: ×25,000). In confocal laser microscopy, MPs appeared as elements with a diameter less than 1 μm and stained for αvβ3 ( c ) and <t>E-selectin</t> ( d ) in vitro. In vivo–generated MPs expressed αvβ3 ( g ) and CD41/GPIIb-IIIa ( h ). In this case, the majority of the elements were positive for CD41 ( h ), whereas only about 10% were positive for αvβ3 ( g ), confirming that they originate from ECs (final magnification: ×1,000). ( b and f ) Negative staining using isotope control IgG1.
    E Selectin, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/e selectin/product/Boehringer Ingelheim
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    e selectin - by Bioz Stars, 2020-07
    92/100 stars
      Buy from Supplier

    85
    Boehringer Ingelheim monoclonal igg4 type antibody mab04c
    Coomassie blue stained none-reducing SDS-PAGE of <t>mAb04c</t> before and after crystallization or protein A purification. 7 µg of <t>IgG</t> was loaded per lane. Lanes: (1) clarified mAb04c culture supernatant; (2) washed mAb04c crystals, redissolved in 100 mM sodium acetate pH 4.0; (3) mAb04c, purified via protein A chromatography.
    Monoclonal Igg4 Type Antibody Mab04c, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monoclonal igg4 type antibody mab04c/product/Boehringer Ingelheim
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    monoclonal igg4 type antibody mab04c - by Bioz Stars, 2020-07
    85/100 stars
      Buy from Supplier

    92
    Boehringer Ingelheim igg isotype control antibody
    Combined treatment of IGF blocking antibody with <t>paclitaxel</t> decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control <t>IgG</t> antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test
    Igg Isotype Control Antibody, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 92/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igg isotype control antibody/product/Boehringer Ingelheim
    Average 92 stars, based on 2 article reviews
    Price from $9.99 to $1999.99
    igg isotype control antibody - by Bioz Stars, 2020-07
    92/100 stars
      Buy from Supplier

    Image Search Results


    Transmission electron and confocal laser microscopy of MPs. Transmission electron microscopy appearance of MPs generated in vitro ( a ) or in vivo ( e ), i.e., isolated from normal plasma (final magnification: ×25,000). In confocal laser microscopy, MPs appeared as elements with a diameter less than 1 μm and stained for αvβ3 ( c ) and E-selectin ( d ) in vitro. In vivo–generated MPs expressed αvβ3 ( g ) and CD41/GPIIb-IIIa ( h ). In this case, the majority of the elements were positive for CD41 ( h ), whereas only about 10% were positive for αvβ3 ( g ), confirming that they originate from ECs (final magnification: ×1,000). ( b and f ) Negative staining using isotope control IgG1.

    Journal: Journal of Clinical Investigation

    Article Title: In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant

    doi:

    Figure Lengend Snippet: Transmission electron and confocal laser microscopy of MPs. Transmission electron microscopy appearance of MPs generated in vitro ( a ) or in vivo ( e ), i.e., isolated from normal plasma (final magnification: ×25,000). In confocal laser microscopy, MPs appeared as elements with a diameter less than 1 μm and stained for αvβ3 ( c ) and E-selectin ( d ) in vitro. In vivo–generated MPs expressed αvβ3 ( g ) and CD41/GPIIb-IIIa ( h ). In this case, the majority of the elements were positive for CD41 ( h ), whereas only about 10% were positive for αvβ3 ( g ), confirming that they originate from ECs (final magnification: ×1,000). ( b and f ) Negative staining using isotope control IgG1.

    Article Snippet: FITC-conjugated mAb to vitronectin receptor (anti-αvβ3 or anti-CD51, clone AMF7, IgG1) was from Immunotech (Marseille, France), and FITC-conjugated mAb to E-selectin (anti-CD62E, clone CI26CIOB7, IgG2a) was from Boehringer Ingelheim Bioproducts (Gagny, France).

    Techniques: Transmission Assay, Microscopy, Electron Microscopy, Generated, In Vitro, In Vivo, Isolation, Staining, Negative Staining

    Coomassie blue stained none-reducing SDS-PAGE of mAb04c before and after crystallization or protein A purification. 7 µg of IgG was loaded per lane. Lanes: (1) clarified mAb04c culture supernatant; (2) washed mAb04c crystals, redissolved in 100 mM sodium acetate pH 4.0; (3) mAb04c, purified via protein A chromatography.

    Journal: PLoS ONE

    Article Title: Towards Protein Crystallization as a Process Step in Downstream Processing of Therapeutic Antibodies: Screening and Optimization at Microbatch Scale

    doi: 10.1371/journal.pone.0025282

    Figure Lengend Snippet: Coomassie blue stained none-reducing SDS-PAGE of mAb04c before and after crystallization or protein A purification. 7 µg of IgG was loaded per lane. Lanes: (1) clarified mAb04c culture supernatant; (2) washed mAb04c crystals, redissolved in 100 mM sodium acetate pH 4.0; (3) mAb04c, purified via protein A chromatography.

    Article Snippet: Antibody Clarified cell culture supernatant of a CHO derived cell line secreting monoclonal IgG4 type antibody mAb04c as well as Protein A-purified mAb04c were kindly provided by Boehringer Ingelheim Pharma GmbH (Biberach, Germany).

    Techniques: Staining, SDS Page, Crystallization Assay, Purification, Chromatography

    Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

    Journal: Oncogene

    Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

    doi: 10.1038/s41388-017-0115-x

    Figure Lengend Snippet: Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

    Article Snippet: Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days.

    Techniques: Blocking Assay, Luciferase, Mouse Assay, Immunohistochemistry, Staining

    Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

    Journal: Oncogene

    Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

    doi: 10.1038/s41388-017-0115-x

    Figure Lengend Snippet: Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

    Article Snippet: Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days.

    Techniques: Blocking Assay, Luciferase, Mouse Assay, Staining, Software, Derivative Assay

    Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

    Journal: Oncogene

    Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

    doi: 10.1038/s41388-017-0115-x

    Figure Lengend Snippet: Combined treatment of IGF blocking antibody with paclitaxel decreases breast cancer proliferation and metastasis in Py230 model. a Py230 luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic C57BL/6 recipient mice and mice were treated, starting when tumors reached between 5–8 mm 2 , twice a week i.p., with control IgG antibody, IGF blocking antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of xentuzumab with paclitaxel ( n = 8 mice per group). b Immunohistochemical staining of phospho-insulin/IGF-1R in breast tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. Scale bars 100 μm and 50 μm . c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with IgG (control), paclitaxel, xentuzumab or paclitaxel + xentuzumab. 3–5 fields counted/mouse tumor, n = 3–4 mice per treatment group, * p ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. e Percentage of mice presenting with lung metastasis per treatment group. ( n = 8 mice/group). f Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. ns, non-significant differences using one-way ANOVA and Bonferroni post hoc test. g Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. h H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. i Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab, * p ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test

    Article Snippet: Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days.

    Techniques: Blocking Assay, Luciferase, Mouse Assay, Immunohistochemistry, Staining

    Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

    Journal: Oncogene

    Article Title: Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

    doi: 10.1038/s41388-017-0115-x

    Figure Lengend Snippet: Combined IGF blocking antibody with paclitaxel decreases metastatic burden in 4T1 breast cancer model. a 4T1-zsgreen/luciferase cells were orthotopically implanted into the third mammary fatpad of syngeneic Balb/c recipient mice and were treated when tumors reached ~ 5 mm mean diameter, over 2 weeks the mice received four treatments by i.p. with control human IgG antibody ( n = 8 mice), IGF blocking antibody xentuzumab (100 mg/kg) ( n = 8 mice), paclitaxel (100 mg/kg) ( n = 9 mice) or a combination of xentuzumab with paclitaxel ( n = 9 mice). b Graph showing tumor mean diameter (mm 2 ) measured by calipers before and during treatment with isotype control, xentuzumab, paclitaxel, and paclitaxel with xentuzumab. Error bars represent s.e. (IgG antibody and xentuzumab n = 8, paclitaxel and paclitaxel with xentuzumab n = 9), * p -value ≤ 0.05, ** p -value ≤ 0.01 using two-way ANOVA and Bonferroni post hoc test. c Immunofluorescent staining of Ki67 in primary tumors treated with IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. d Quantification of Ki67-positive tumor cells in tumors treated with human IgG (control), paclitaxel, xentuzumab, or paclitaxel + xentuzumab. A total of 3–5 fields counted/mouse tumor, n = 8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 0.0001 p using one-way ANOVA and Bonferroni post hoc test. Images quantified using NIS-Elements Advanced Research software. e Quantification of number of lung metastatic foci per 100mm 2 in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e. (IgG antibody n = 7, paclitaxel n = 9, xentuzumab n = 8, and paclitaxel with xentuzumab n = 9) ns, non-significant differences, * p -value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. f Average size of pulmonary metastatic lesions (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. g H E staining of lung metastatic foci in mice treated with control IgG, paclitaxel, xentuzumab, or paclitaxel + xentuzumab. Scale bar 50 μm. h Total metastatic burden (mm 2 ) in mice treated with control IgG, paclitaxel, xentuzumab, and paclitaxel with xentuzumab. Error bars represent s.e., ns, non-significant differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. i Schematics describing the role of stroma-derived IGF-1 and 2 in regulating the response of metastatic breast cancer to paclitaxel

    Article Snippet: Mice were administered i.p with IgG isotype control antibody, paclitaxel (100 mg/kg), IGF-1/2 blocking antibody xentuzumab (100 mg/kg) [ ] kindly provided by Boehringer Ingelheim, or Paclitaxel with xentuzumab, twice a week for 15 days.

    Techniques: Blocking Assay, Luciferase, Mouse Assay, Staining, Software, Derivative Assay